At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

In an analysis of Medicare's top-selling brand-name oncology drugs, researchers found that while the vast majority provided ...

As of 11:14:47 AM EDT. Market Open.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.